Jason Gilbert, MD
Instructor, Medicine-Hospital Medicine

Publications

• Madarang E, Lykon J, Zhao W, Sekeres M, Bradley T, Chandhok N, Taylor J, Venugopal S, Koru-Sengul T, Iyer S, Gilbert JS, Miller R, Nanni J, Zacheo I, Mattei A, Ali N, Kishtagari A, Marconi G, Sallman D, Pollyea DA, Savona M, Papayannidis C, Komrokji R, Watts J. Venetoclax and Hypomethylating Agents in Octo- and Nonagenarians with Acute Myeloid Leukemia. Blood Neoplasia, 2024.
• Marvin-Peek J, Gilbert JS, Pollyea DA, DiNardo C. Frontline Therapy of AML with Lower Intensity Regimens – Where are we now and where can we go? American Journal of Hematology. July 2024.
• Khanna V, Azenkot T, Liu SQ, Gilbert JS, Cheung E, Lau K, Pollyea DA, Traer E, Jonas BA, Zhang TY, Mannis GN. Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis. Leuk Res. 2023 Aug;131:107331. PubMed PMID: 37263072
• Hanumanthu BKJ, Nair AS, Katamreddy A, Gilbert JS, You JY, Offor OL, Kushwaha A, Krishnan A, Napolitano M, Palaidimos L, Morante J, Tekwani SS, Mehta S, Gupta A, Goraya H, Sun M, Faillace RT, Gulani P. Sepsis-induced cardiomyopathy is associated with higher mortality rates in patients with sepsis. Acute Crit Care. 2021 Aug;36(3):215-222. PubMed PMID: 34311515